RxDoctor Payments Data

Armine Nazaryan, MD

Family Medicine · Glendale, CANPI 1972505444

Payments from drug & device makers

$12,490in general payments, 2019–2025

Across 587 payments — averaging $21.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$1K
  • AstraZeneca$741
  • Amgen$633
  • Boehringer Ingelheim$609
  • Sanofi-aventis U.S. LLC$563
  • plus $7K from 54 others

What the payments were for

  • Food & beverage$12,37199%
  • Education$851%
  • Gifts$340%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)84$1,690
Novo Nordisk69$1,257
AstraZeneca37$741
Amgen(2 entities)25$633
Boehringer Ingelheim28$609
Sanofi-aventis U.S. LLC28$563
Novartis29$540
Ironwood Pharmaceuticals, Inc25$519
Lilly USA, LLC22$507
Abbott10$426
Bayer15$419
GSK21$415
Astellas Pharma US Inc18$364
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC20$346
Redhill Biopharma Inc.10$251
Amarin Pharma, Inc.8$213
Merck10$201
Lundbeck LLC7$184
Scilex Pharmaceuticals Inc.9$157
Aimmune Therapeutics, Inc.5$150
Takeda Pharmaceuticals U.S.A., Inc.9$146
Esperion Therapeutics, Inc.7$141
Pfizer7$140
Xeris Pharmaceuticals, Inc.6$135
Dexcom, Inc.6$122
Sunovion Pharmaceuticals Inc.5$103
Axsome Therapeutics, Inc.3$101
Biohaven Pharmaceuticals, Inc.4$94
Biohaven Pharmaceutical Holding Company Ltd.4$94
Nestle Healthcare Nutrition Inc.4$92
Vivus LLC4$92
Idorsia Pharmaceuticals US Inc5$82
Phathom Pharmaceuticals, Inc.4$80
Angiodynamics, Inc.1$69
Ardelyx, Inc.2$65
Abiomed2$59
Almatica Pharma LLC3$55
Smith+Nephew3$55
Ascend Therapeutics US, LLC3$53
Avanir Pharmaceuticals, Inc.2$50
Eisai Inc.3$49
Madrigal Pharmaceuticals2$43
Bristol Myers Squibb1$31
Lexicon Pharmaceuticals, Inc.1$30
Exact Sciences1$30
Echosens North America, Inc.1$26
Concordia Pharmaceuticals Inc.1$24
Hikma Pharmaceuticals USA1$23
Eyevance Pharmaceuticals LLC1$23
Johnson & Johnson1$23
Arbor Pharmaceuticals, Inc.1$22
Regeneron Healthcare Solutions, Inc.1$21
Sun Pharmaceutical Industries Inc.1$20
IBSA Pharma Inc.1$19
Tersera Therapeutics LLC1$18
Tonix Medicines, Inc.1$17
Shield Therapeutics Inc1$17
Medtronic1$15
Medicure Pharma Inc.1$15
Zyla Life Sciences, Inc.1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,490 in reported general payments places this provider in the 95th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$542,087
Medicare patients
1,385
Services billed
10,224

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanumetSitagliptin Phos/Metformin Hcl1,001$568,707
OzempicSemaglutide498$477,423
JardianceEmpagliflozin633$388,259
LinzessLinaclotide597$316,475
TrulicityDulaglutide273$268,088
CreonLipase/Protease/Amylase330$258,208
ZenpepLipase/Protease/Amylase236$233,301
EliquisApixaban344$214,278
SynjardyEmpagliflozin/Metformin Hcl343$204,246
JanuviaSitagliptin Phosphate359$199,096
JentaduetoLinagliptin/Metformin Hcl371$191,901
FarxigaDapagliflozin Propanediol301$177,545
EntrestoSacubitril/Valsartan204$137,840
MyrbetriqMirabegron300$134,748
TradjentaLinagliptin225$121,664

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Synjardy, Jentadueto, Tradjenta$609$906,0701,572 claims
MerckJanumet, Januvia, Belsomra$201$790,2881,415 claims
AbbVieLinzess, Creon, Ubrelvy$1,690$612,696964 claims
Novo NordiskOzempic, Rybelsus$1,257$551,031575 claims
Lilly USA, LLCTrulicity, Mounjaro$507$350,966352 claims
Aimmune Therapeutics, Inc.Zenpep$150$233,301236 claims
PfizerEliquis$140$214,278344 claims
AstraZenecaFarxiga, Brilinta$741$202,802361 claims
NovartisEntresto$540$137,840204 claims
Astellas Pharma US IncMyrbetriq$364$134,748300 claims
GSKBreo Ellipta, Trelegy Ellipta, Anoro Ellipta$415$122,423268 claims
AmgenProlia$633$90,85454 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,533 family medicine providers in California.

Other family medicine in Glendale

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →